Novel Therapies for B-Cell Lymphomas
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 15 December 2025 | Viewed by 25
Special Issue Editor
Special Issue Information
Dear Colleagues,
B-cell lymphomas are a diverse group of blood cancers originating in B lymphocytes, accounting for approximately 85% of all non-Hodgkin lymphomas. These malignancies range from aggressive subtypes, such as diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma, to indolent forms such as follicular lymphoma and chronic lymphocytic leukemia (CLL). While traditional treatments such as chemotherapy, radiation, and immunotherapy have improved patient outcomes, challenges remain, including treatment resistance and disease recurrence. Recent advances in targeted therapies, CAR-T cell therapy, bispecific antibodies, and small-molecule inhibitors offer promising new strategies. This Special Issue will highlight the latest developments in B-cell lymphoma treatment, focusing on novel therapeutic approaches, biomarker-driven treatment strategies, and translational research to enhance patient outcomes. We welcome both original research articles and review papers that explore cutting-edge innovations, clinical trials, and future directions in the management of B-cell lymphomas.
Dr. David MacDonald
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- B-cell lymphomas
- non-Hodgkin lymphomas
- targeted therapy
- CAR-T cell therapy
- bispecific antibodies
- biomarker-driven treatment
- translational research
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
